$ICU
SeaStar Medical Holding Corp

2023 Q3 Form 10-Q Financial Statement

#000095017023042517 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.829M $1.740M $720.0K
YoY Change 75.87% 141.67% 243.31%
% of Gross Profit
Research & Development $1.107M $2.007M $596.0K
YoY Change 51.64% 236.74% 10.37%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.936M $3.750M $341.8K
YoY Change 65.88% 997.2% 62.97%
Operating Profit -$2.936M -$3.750M -$1.404M
YoY Change 76.67% 167.14% 569.35%
Interest Expense $224.0K $225.0K $1.586M
YoY Change -286.67% -85.82% -189.47%
% of Operating Profit
Other Income/Expense, Net -$4.490M $86.00K $410.0K
YoY Change -79.02% 355.56%
Pretax Income -$7.426M -$3.664M $182.6K
YoY Change 292.91% -2107.01% -109.21%
Income Tax $0.00 $5.000K $0.00
% Of Pretax Income 0.0%
Net Earnings -$7.426M -$3.669M $182.6K
YoY Change 1098.46% -2109.73% -109.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37 -$0.25 -$0.12
Diluted Earnings Per Share -$0.37 -$0.25 $14.00K
COMMON SHARES
Basic Shares Outstanding 18.57M 13.45M 7.239M
Diluted Shares Outstanding 20.05M 14.93M 7.239M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.00K $10.00K $79.02K
YoY Change 46.0% -87.34% -76.74%
Cash & Equivalents $73.00K $13.00K $79.02K
Short-Term Investments
Other Short-Term Assets $2.172M $2.320M $105.9M
YoY Change 106.86% -97.81% 17212.99%
Inventory
Prepaid Expenses $2.172M $2.319M $188.9K
Receivables
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.245M $2.332M $106.0M
YoY Change -97.91% -97.8% 11038.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000K $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $2.000K $2.000K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $2.245M $2.332M $106.0M
Total Long-Term Assets $2.000K $2.000K $0.00
Total Assets $2.247M $2.334M $106.0M
YoY Change -97.91% -97.8% -0.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.042M $4.355M $670.0K
YoY Change 290.85% 550.0%
Accrued Expenses $1.481M $1.095M $1.037M
YoY Change 76.31% 5.55% 2003.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $911.9K
YoY Change -100.0% -100.0%
Long-Term Debt Due $4.405M $5.907M $2.550M
YoY Change 974.39% 131.65%
Total Short-Term Liabilities $12.43M $13.78M $7.382M
YoY Change 32.41% 86.7% 3738.87%
LONG-TERM LIABILITIES
Long-Term Debt $5.722M $0.00 $0.00
YoY Change 39.22%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $5.722M $0.00 $0.00
YoY Change 39.22% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.43M $13.78M $7.382M
Total Long-Term Liabilities $5.722M $0.00 $0.00
Total Liabilities $18.15M $13.78M $7.382M
YoY Change 93.37% 86.7% -37.83%
SHAREHOLDERS EQUITY
Retained Earnings -$115.7M -$108.3M -$6.997M
YoY Change 1200.45% 1447.15% -35.91%
Common Stock $3.000K $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.90M -$11.45M -$6.997M
YoY Change
Total Liabilities & Shareholders Equity $2.247M $2.334M $106.0M
YoY Change -97.91% -97.8% -0.54%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$7.426M -$3.669M $182.6K
YoY Change 1098.46% -2109.73% -109.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.340M -$2.170M -$611.0K
YoY Change 47.25% 255.17% 1464.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.396M 1.460M 601.9K
YoY Change 298.86% 142.55% -598.21%
NET CHANGE
Cash From Operating Activities -1.340M -2.170M -611.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 1.396M 1.460M 601.9K
Net Change In Cash 56.00K -710.0K -9.040K
YoY Change -110.0% 7753.98% -94.47%
FREE CASH FLOW
Cash From Operating Activities -$1.340M -$2.170M -$611.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001831868
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39927
dei Entity Registrant Name
EntityRegistrantName
SEASTAR MEDICAL HOLDING CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3681132
dei Entity Address Address Line1
EntityAddressAddressLine1
3513 Brighton Blvd.,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 410
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80216
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
427-8100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18570971
CY2023Q2 us-gaap Cash
Cash
13000
CY2022Q4 us-gaap Cash
Cash
47000
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
12000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2319000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2977000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
2332000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3036000
CY2023Q2 icu Prepaid Forward Contracts
PrepaidForwardContracts
0
CY2022Q4 icu Prepaid Forward Contracts
PrepaidForwardContracts
1729000
CY2023Q2 us-gaap Other Assets
OtherAssets
2000
CY2022Q4 us-gaap Other Assets
OtherAssets
2000
CY2023Q2 us-gaap Assets
Assets
2334000
CY2022Q4 us-gaap Assets
Assets
4767000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4355000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1927000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1095000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2245000
CY2023Q2 icu Contingent Upfront Payment For License Agreement
ContingentUpfrontPaymentForLicenseAgreement
100000
CY2022Q4 icu Contingent Upfront Payment For License Agreement
ContingentUpfrontPaymentForLicenseAgreement
0
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
5907000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1178000
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2230000
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2023Q2 icu Warrants Liability
WarrantsLiability
95000
CY2022Q4 icu Warrants Liability
WarrantsLiability
0
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13782000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5350000
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
7652000
CY2023Q2 us-gaap Liabilities
Liabilities
13782000
CY2022Q4 us-gaap Liabilities
Liabilities
13002000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18121238
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18121238
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12699668
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12699668
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96806000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
91089000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108256000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99325000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-11448000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8235000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2334000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4767000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2007000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
596000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3791000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
951000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1743000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
716000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4540000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1173000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3750000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1312000
us-gaap Operating Expenses
OperatingExpenses
8331000
us-gaap Operating Expenses
OperatingExpenses
2124000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3750000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1312000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8331000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2124000
CY2023Q2 us-gaap Interest Expense
InterestExpense
225000
CY2022Q2 us-gaap Interest Expense
InterestExpense
191000
us-gaap Interest Expense
InterestExpense
658000
us-gaap Interest Expense
InterestExpense
360000
CY2023Q2 icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
-100000
CY2022Q2 icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
0
icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
0
icu Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
0
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-480000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-480000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2023Q2 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
0
CY2022Q2 us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
-601000
us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
0
us-gaap Increase Decrease In Notes Payable Current
IncreaseDecreaseInNotesPayableCurrent
-578000
CY2023Q2 icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
69000
CY2022Q2 icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
0
icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
1723000
icu Change In Fair Value Of Forward Option Prepaid Forward Contracts
ChangeInFairValueOfForwardOptionPrepaidForwardContracts
0
CY2023Q2 icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
0
CY2022Q2 icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
0
icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
1306000
icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
410000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-595000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
218000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3664000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-902000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8926000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1906000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3669000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-902000
us-gaap Profit Loss
ProfitLoss
-8931000
us-gaap Profit Loss
ProfitLoss
-1906000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14932866
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14932866
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7238767
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7238767
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13984625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13984625
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7238767
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7238767
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2816000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1004000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3816000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
345000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-902000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-4373000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8235000
CY2023Q1 icu Stock Issued During Period Value Equity Line Of Credit
StockIssuedDuringPeriodValueEquityLineOfCredit
1108000
CY2023Q1 icu Stock Issued During Period Value Commitment Fee For Equity Line
StockIssuedDuringPeriodValueCommitmentFeeForEquityLine
1000000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
505000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5262000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-10884000
CY2023Q2 icu Stock Issued During Period Value Equity Line Of Credit
StockIssuedDuringPeriodValueEquityLineOfCredit
55000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1937000
CY2023Q2 icu Stock Issued During Period Value Prepaid Forward Contracts
StockIssuedDuringPeriodValuePrepaidForwardContracts
558000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
555000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3669000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-11448000
us-gaap Profit Loss
ProfitLoss
-8931000
us-gaap Profit Loss
ProfitLoss
-1906000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
208000
icu Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
23000
icu Amortization Of Deferred Financing Costs
AmortizationOfDeferredFinancingCosts
0
icu Non Cash Accrued Interest Added To Principal Of Notes Payable
NonCashAccruedInterestAddedToPrincipalOfNotesPayable
0
icu Non Cash Accrued Interest Added To Principal Of Notes Payable
NonCashAccruedInterestAddedToPrincipalOfNotesPayable
-151000
icu Non Cash Conversion Of Accrued Expenses Into Notes Payable
NonCashConversionOfAccruedExpensesIntoNotesPayable
0
icu Non Cash Conversion Of Accrued Expenses Into Notes Payable
NonCashConversionOfAccruedExpensesIntoNotesPayable
-96000
icu Non Cash Fair Value Of Discount On Issuance Of Notes Payable
NonCashFairValueOfDiscountOnIssuanceOfNotesPayable
0
icu Non Cash Fair Value Of Discount On Issuance Of Notes Payable
NonCashFairValueOfDiscountOnIssuanceOfNotesPayable
52000
icu Non Cash Fair Value Of Derivative Liability On Issuance Of Notes Payable
NonCashFairValueOfDerivativeLiabilityOnIssuanceOfNotesPayable
0
icu Non Cash Fair Value Of Derivative Liability On Issuance Of Notes Payable
NonCashFairValueOfDerivativeLiabilityOnIssuanceOfNotesPayable
-52000
icu Increase Decrease In Notes Payable
IncreaseDecreaseInNotesPayable
0
icu Increase Decrease In Notes Payable
IncreaseDecreaseInNotesPayable
-578000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-480000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
icu Change In Fair Value Of Forward Option
ChangeInFairValueOfForwardOption
1723000
icu Change In Fair Value Of Forward Option
ChangeInFairValueOfForwardOption
0
icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
1306000
icu Gain Loss On Sale Of Recycled Shares
GainLossOnSaleOfRecycledShares
0
us-gaap Share Based Compensation
ShareBasedCompensation
1060000
us-gaap Share Based Compensation
ShareBasedCompensation
349000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-12000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-658000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
777000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2428000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
584000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
350000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
295000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4463000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1578000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
258000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1163000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
icu Payment Of Commitment Fee Equity Line Of Credit
PaymentOfCommitmentFeeEquityLineOfCredit
500000
icu Payment Of Commitment Fee Equity Line Of Credit
PaymentOfCommitmentFeeEquityLineOfCredit
0
icu Proceeds From Sale Of Recycled Shares
ProceedsFromSaleOfRecycledShares
1870000
icu Proceeds From Sale Of Recycled Shares
ProceedsFromSaleOfRecycledShares
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
100000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1681000
icu Payment Of Notes Payable
PaymentOfNotesPayable
2946000
icu Payment Of Notes Payable
PaymentOfNotesPayable
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4429000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1681000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-34000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
103000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
510000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
613000
us-gaap Interest Paid Net
InterestPaidNet
675000
us-gaap Interest Paid Net
InterestPaidNet
0
icu Shares Issued As Payment Of Convertible Notes
SharesIssuedAsPaymentOfConvertibleNotes
1937000
icu Shares Issued As Payment Of Convertible Notes
SharesIssuedAsPaymentOfConvertibleNotes
0
icu Shares Issued To Settle Forward Option Prepaid Forward Contracts
SharesIssuedToSettleForwardOptionPrepaidForwardContracts
558000
icu Shares Issued To Settle Forward Option Prepaid Forward Contracts
SharesIssuedToSettleForwardOptionPrepaidForwardContracts
0
icu Issuance Of Convertible Note Warrant
IssuanceOfConvertibleNoteWarrant
575000
icu Issuance Of Convertible Note Warrant
IssuanceOfConvertibleNoteWarrant
0
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108256000
CY2023Q2 us-gaap Cash
Cash
13000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the forward option on prepaid forward contracts, derivative liability, warrants, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentrations of credit risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. The Company has not experienced any losses on deposits since inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 icu Accrued Commitment Fee Equity Line Of Credit
AccruedCommitmentFeeEquityLineOfCredit
0
CY2022Q4 icu Accrued Commitment Fee Equity Line Of Credit
AccruedCommitmentFeeEquityLineOfCredit
1500000
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
502000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
450000
CY2023Q2 icu Accrued Director Remuneration Current
AccruedDirectorRemunerationCurrent
244000
CY2022Q4 icu Accrued Director Remuneration Current
AccruedDirectorRemunerationCurrent
61000
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
150000
CY2022Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
0
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
72000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
112000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
51000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
80000
CY2023Q2 icu Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
19000
CY2022Q4 icu Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
18000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1095000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2245000
CY2023Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
98837000
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
77000
CY2023Q2 us-gaap Notes Payable
NotesPayable
5907000
CY2022Q4 us-gaap Notes Payable
NotesPayable
8830000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
5907000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1178000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
7652000
CY2023Q2 icu Future Maturities Of Principal Repayment Of Convertible Notes Remainder Of Fiscal Year
FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesRemainderOfFiscalYear
0
CY2023Q2 icu Future Maturities Of Principal Repayment Of Convertible Notes Next Twelve Months
FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesNextTwelveMonths
5907000
CY2023Q2 icu Future Maturities Of Principal Repayment Of Convertible Notes Due
FutureMaturitiesOfPrincipalRepaymentOfConvertibleNotesDue
5907000
CY2022Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
99000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
208000
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
17404967
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
16857714
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
555000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
345000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1060000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349000
CY2023Q2 icu Contingent Upfront Payment For License Agreement
ContingentUpfrontPaymentForLicenseAgreement
100000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
8000
us-gaap Operating Lease Expense
OperatingLeaseExpense
16000
us-gaap Operating Lease Expense
OperatingLeaseExpense
16000
CY2023Q2 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
150000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18012515
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
698954
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17739234
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
553984
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3669000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-902000
us-gaap Net Income Loss
NetIncomeLoss
-8931000
us-gaap Net Income Loss
NetIncomeLoss
-1906000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14932866
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14932866
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7238767
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7238767
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13984625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13984625
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7238767
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7238767
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26

Files In Submission

Name View Source Status
icu-20230630_pre.xml Edgar Link unprocessable
0000950170-23-042517-index-headers.html Edgar Link pending
0000950170-23-042517-index.html Edgar Link pending
0000950170-23-042517.txt Edgar Link pending
0000950170-23-042517-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
icu-20230630.htm Edgar Link pending
icu-20230630.xsd Edgar Link pending
icu-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
icu-20230630_def.xml Edgar Link unprocessable
icu-ex10_1.htm Edgar Link pending
icu-ex31_1.htm Edgar Link pending
icu-ex31_2.htm Edgar Link pending
icu-ex32_1.htm Edgar Link pending
icu-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
icu-20230630_lab.xml Edgar Link unprocessable
icu-20230630_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending